Latest news with #BrianMarkison
Yahoo
09-05-2025
- Business
- Yahoo
LNTH Q1 Earnings Call: Lantheus Lowers Outlook Amid Product Shifts and Divestitures
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) missed Wall Street's revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company's full-year revenue guidance of $1.57 billion at the midpoint came in 1.8% below analysts' estimates. Its non-GAAP profit of $1.53 per share was 7.5% below analysts' consensus estimates. Is now the time to buy LNTH? Find out in our full research report (it's free). Revenue: $372.8 million vs analyst estimates of $378.8 million (flat year on year, 1.6% miss) Adjusted EPS: $1.53 vs analyst expectations of $1.65 (7.5% miss) Adjusted EBITDA: $149.6 million vs analyst estimates of $172.9 million (40.1% margin, 13.4% miss) The company dropped its revenue guidance for the full year to $1.57 billion at the midpoint from $1.58 billion, a 0.6% decrease Management lowered its full-year Adjusted EPS guidance to $6.65 at the midpoint, a 6.3% decrease Operating Margin: 27.4%, down from 28.8% in the same quarter last year Free Cash Flow Margin: 26.5%, down from 32.2% in the same quarter last year Market Capitalization: $5.57 billion Lantheus Holdings' first quarter results were driven by a combination of steady performance from its core imaging agents and significant business transformation initiatives. Management attributed the quarter's results to the impact of contracting strategies in its radiopharmaceutical segment, ongoing competitive dynamics in its PYLARIFY product, and the divestiture of its SPECT business. CEO Brian Markison emphasized, 'We are laying the foundation for the next chapter of our business,' highlighting the importance of recent acquisitions and a focus on PET radiodiagnostics and radiotherapeutics. Looking ahead, Lantheus' downward adjustment of full-year guidance was shaped by a more cautious view on PYLARIFY's growth trajectory and anticipated integration costs from new acquisitions. Management remains focused on streamlining its portfolio, expanding its Alzheimer's disease diagnostics via the Life Molecular Imaging acquisition, and investing in early- and late-stage pipeline assets. Markison noted that these moves are designed to 'diversify our revenue streams and unlock additional value,' though leadership acknowledged ongoing headwinds in reimbursement and market competition. Lantheus' leadership pointed to ongoing portfolio realignment and competitive pressure as key influences on first quarter outcomes. The company's business update centered around the strategic sale of its SPECT business, acquisitions targeting growth in PET imaging, and the positioning of its pipeline for future expansion. Portfolio transformation underway: Management is actively shifting away from legacy SPECT imaging, opting to divest this segment to SHINE Technologies. This streamlining move is intended to focus the company on higher-margin PET diagnostics and radiotherapeutics. Acquisition-driven pipeline expansion: The completed Evergreen Theragnostics acquisition and pending Life Molecular Imaging (LMI) deal are expected to add commercial products and expand the pipeline, particularly in neuroendocrine tumor imaging and Alzheimer's diagnostics. Evergreen brings manufacturing capabilities and a pipeline that includes OCTEVY, while LMI adds NEURACEQ, a PET imaging agent for Alzheimer's disease. PYLARIFY market dynamics: PYLARIFY, Lantheus' PSMA PET imaging agent, saw continued volume growth offset by a low-single-digit decline in net price. Management cited increased competitive disruption among smaller, non-contracted imaging centers due to reimbursement changes, but believes expanded contracting and product availability will help regain momentum. Alzheimer's diagnostics opportunity: The company anticipates significant growth in the Alzheimer's PET imaging market, citing over 100 therapeutic candidates in development. Management expects its combined Alzheimer's diagnostics platform to be positioned for leadership as the market expands. Margin pressures and cost allocation: Operating margins declined in part due to increased R&D spend supporting a broader pipeline and non-recurring transaction expenses. The company expects divesting lower-margin businesses and integrating acquisitions to support future margin improvement. Management's outlook for the remainder of the year is shaped by the integration of new acquisitions, ongoing reimbursement headwinds in core imaging agents, and anticipated growth in the Alzheimer's diagnostics market. Integration of new acquisitions: Lantheus expects the addition of Evergreen and LMI to diversify its revenue base and provide new growth avenues, though near-term earnings will be diluted by integration costs and increased R&D investment. Reimbursement environment and competition: Ongoing changes in Medicare reimbursement and heightened competition, especially for PYLARIFY, are expected to impact near-term growth and pricing power. Management is focused on expanding contracting efforts to smaller imaging centers to mitigate these effects. Alzheimer's diagnostics and pipeline launches: The company believes growth in Alzheimer's disease PET imaging will accelerate with the launch of new diagnostic agents and continued development of therapeutic partnerships, positioning Lantheus to benefit from increasing demand in this area. Anthony Petrone (Mizuho Financial Group): Asked about PYLARIFY's competitive dynamics and the rationale for divesting the SPECT business; management described short-term disruptions among smaller centers and emphasized a focus on growth platforms. Roanna Ruiz (Leerink Partners): Queried about drivers for the narrowed guidance range and how resources from the SPECT sale would be redeployed; management cited more cautious PYLARIFY assumptions and a focus on PET diagnostics and radiotherapeutics. Richard Newitter (Truist Securities): Sought clarity on expected dilution from acquisitions and whether double-digit revenue growth in 2026 remains likely; management reiterated low-single-digit dilution and stated that double-digit growth is still anticipated with full-year contributions from acquisitions. Matt Taylor (Jefferies): Asked how the acquisitions would affect growth rates in 2026 and beyond; management pointed to launches of OCTEVY, PNT2003, and Alzheimer's agents as potential drivers for sustained double-digit growth. Paul Choi (Goldman Sachs): Inquired about PYLARIFY pricing trends and the outlook for Alzheimer's PET scan market growth post-acquisition; leadership highlighted ongoing payer discussions and robust growth in Alzheimer's imaging claims. In future quarters, the StockStory team will watch (1) the pace and success of Evergreen and Life Molecular Imaging integration, (2) stabilization and potential recovery in PYLARIFY's pricing and volume trends as new contracting strategies are implemented, and (3) early signs of expansion in the Alzheimer's PET imaging segment following NEURACEQ's addition. The timing of key regulatory filings and product launches will also be critical markers for the company's evolving growth trajectory. Lantheus currently trades at a forward P/E ratio of 11.2×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
Yahoo
07-05-2025
- Business
- Yahoo
Lantheus (NASDAQ:LNTH) Reports Sales Below Analyst Estimates In Q1 Earnings, Stock Drops
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Lantheus's annualized revenue growth of 22.3% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last five years, Lantheus grew its sales at an incredible 34.3% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis. Pioneering the "Find, Fight and Follow" approach to disease management, Lantheus Holdings (NASDAQGM:LNTH) develops and commercializes radiopharmaceuticals and other imaging agents that help healthcare professionals detect, diagnose, and treat diseases. "We are laying the foundation for the next chapter of Lantheus' business with the acquisition of Evergreen Theragnostics and planned acquisition of Life Molecular Imaging, both of which add growth drivers that complement our business and diversify our revenues. These transactions also add exciting new pipeline programs in both late- and early-stage development and key capabilities that enable Lantheus to progress novel programs from bench to clinic," said Brian Markison, Chief Executive Officer at Lantheus. The company dropped its revenue guidance for the full year to $1.57 billion at the midpoint from $1.58 billion, a 0.6% decrease Is now the time to buy Lantheus? Find out in our full research report . Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell short of the market's revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company's full-year revenue guidance of $1.57 billion at the midpoint came in 1.5% below analysts' estimates. Its non-GAAP profit of $1.53 per share was 7.5% below analysts' consensus estimates. Story Continues Lantheus Year-On-Year Revenue Growth This quarter, Lantheus's $372.8 million of revenue was flat year on year, falling short of Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to grow 7% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is above the sector average and implies the market is baking in some success for its newer products and services. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Lantheus has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average operating margin of 18.4%. Analyzing the trend in its profitability, Lantheus's operating margin rose by 28.2 percentage points over the last five years, as its sales growth gave it immense operating leverage. This performance was mostly driven by its recent improvements as the company's margin has increased by 32.6 percentage points on a two-year basis. These data points are very encouraging and shows momentum is on its side. Lantheus Trailing 12-Month Operating Margin (GAAP) This quarter, Lantheus generated an operating profit margin of 27.4%, down 1.4 percentage points year on year. This reduction is quite minuscule and indicates the company's overall cost structure has been relatively stable. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Lantheus's EPS grew at an astounding 39.7% compounded annual growth rate over the last five years, higher than its 34.3% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. Lantheus Trailing 12-Month EPS (Non-GAAP) We can take a deeper look into Lantheus's earnings to better understand the drivers of its performance. As we mentioned earlier, Lantheus's operating margin declined this quarter but expanded by 28.2 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals. In Q1, Lantheus reported EPS at $1.53, down from $1.69 in the same quarter last year. This print missed analysts' estimates, but we care more about long-term EPS growth than short-term movements. Over the next 12 months, Wall Street expects Lantheus's full-year EPS of $6.62 to grow 8.6%. Key Takeaways from Lantheus's Q1 Results We struggled to find many positives in these results. Its full-year EPS guidance missed significantly and its EPS fell short of Wall Street's estimates. Overall, this quarter could have been better. The stock traded down 8.3% to $96.07 immediately following the results. Lantheus's earnings report left more to be desired. Let's look forward to see if this quarter has created an opportunity to buy the stock. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free.
Business Journals
21-04-2025
- Business
- Business Journals
In tough environment, Lantheus has cash and plans to use it
By submitting your information you are agreeing to our Privacy Policy and User Agreement . A challenging economic environment is constricting biotech deal flow. But for well-capitalized Lantheus, these tough times present an opportunity to build out its R&D pipeline. Buoyed by a new blockbuster radiodiagnostic, Lantheus Holdings Inc. is now well capitalized in a tough economic environment and rebuilding its R&D pipeline with some new deals. 'We're generating a lot of cash, and we're spending the money on really intelligent, I hope, intelligent, development programs and acquisitions,' CEO Brian Markison told the Business Journal in a recent interview at Lantheus' Bedford headquarters. Markison became CEO of Lantheus (Nasdaq: LNTH) just over one year ago in March 2024. But he's not a new face at the company. He joined Lantheus' board in 2012 and was its chairperson from 2013 until 2024, when he became the chief executive. GET TO KNOW YOUR CITY Find Local Events Near You Connect with a community of local professionals. Explore All Events When Markison first came to Lantheus, it was a very different company, he said. Lantheus was much smaller and owned by private equity. Markison said the company has been through 'a couple of tough patches,' including a 'very difficult period' when troubles with its manufacturing partner meant the supply chain for Definity, a contrasting agent used in echocardiograms, was disrupted and sales dropped. 'We had to cut a lot of expenses. We really cut R&D back,' Markison said. 'When we emerged from that kind of tough period, we invested back in the commercial engine, but we never really had the ability to reinvest in the research and development like we wanted to.' As Definity sales grew and Lantheus went public in 2015, the company had more options to rebuild its R&D engine. Rebuilding Lantheus Markison said he views his leadership as an extension of longtime CEO Mary Anne Heino, who led Lantheus for nine years. 'When I was on the board, I recruited Mary Anne and then promoted her to CEO, and it was probably one of the best moves I've ever made with people. And she did a really great job. And all I'm doing right now is trying to build on everything that she put together and take it to another level,' Markison said. Under Heino's direction, Lantheus completed its merger with New York-based oncology company Progenics Pharmaceuticals in 2020. That deal gave Lantheus Pylarify, a radioactive diagnostic agent for prostate cancer. Pylarify exceeded $1 billion in net sales in 2024, which Lantheus said made it the first-ever blockbuster radiodiagnostic. Lantheus' cash and cash equivalents grew to $912.8 million at the end of 2024, up from $713.7 million the year prior. The success of this Pylarify deal has opened the door for further acquisitions, and Lantheus is taking advantage of the opportunity to build its pipeline. 'Now we're really basically, with recent acquisitions, totally rebuilding the R&D capability,' Markison said. At the start of April 2025, Lantheus completed its acquisition of Evergreen Theragnostics Inc. This marked Lantheus' fifth deal since January 2024. Lantheus said the company's transactions and in-licensing deals in 2024 brought five new assets to its pipeline. 'If we find something that we think could be a leapfrog over internal programs, and the price is right, if you will, then we'll trade up. We'll make that bet. And we have the fortunate position where our lead assets are throwing off a lot of cash. The organization's relatively efficient, so we're able to invest that money and then reshuffle the deck, if you will,' Markison said. Lantheus is now the 21st largest life sciences company in Massachusetts, per Business Journal research. The company employed 808 people at the end of 2024, of which 783 were located in the U.S. In Massachusetts, Lantheus has facilities in North Billerica and Bedford. The life sciences industry is experiencing tough public markets and reduced venture capital availability, leaving some biotechs struggling. That presents an opportunity for companies like Lantheus who are on the hunt for deals. 'I think when a source of funding is dried up momentarily, then we become a fairly attractive source. But we're going to also want something in return, and usually we're going to want some of their promising assets,' Markison said. Don't miss out on Boston-area life science news. Subscribe to the Morning Edition or Afternoon Edition for free.
Yahoo
28-01-2025
- Business
- Yahoo
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus' therapeutic agent, PNT2003 Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs Company reaffirms Full-Year and Fourth Quarter, 2024 financial guidance Company to host conference call on January 28, 2025, at 8:30 AM ET BEDFORD, Mass., Jan. 28, 2025 /PRNewswire/ -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a definitive agreement to acquire Evergreen Theragnostics, Inc. ("Evergreen"), in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments. Evergreen is a clinical-stage radiopharmaceutical company engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary products. This transaction is expected to solidify Lantheus' capabilities as a fully integrated radiopharmaceutical company. The addition of Evergreen's scalable manufacturing capabilities and infrastructure enhances Lantheus' ability to meet the complex demands of radiopharmaceutical development and production. The acquisition also expands Lantheus' oncology diagnostic pipeline by adding both OCTEVY, a registrational-stage PET diagnostic agent for certain neuroendocrine tumors (NETs) that could complement Lantheus' therapeutic candidate PNT2003, as well as a number of clinical and pre-clinical novel theranostic pairs. "As Lantheus continues to advance its industry leadership, this transaction, along with the agreement to acquire Life Molecular Imaging, enhances our operations across the radiopharmaceutical value chain," said Brian Markison, CEO of Lantheus. "With Evergreen's manufacturing and development capabilities, we become fully integrated and will ultimately make a difference in the lives of more patients. We are pleased to welcome Evergreen's talented team to Lantheus and are confident that their expertise in radiopharmaceutical theranostics and culture focused on developing new solutions for cancer patients will enrich our organization." "Today marks an exciting new chapter for Evergreen as we look to join the Lantheus team," said James Cook, CEO of Evergreen. "Lantheus' industry expertise and financial strength will help us bring our innovations to a broad patient population faster and support our mission to improve options for cancer patients through theranostic radiopharmaceuticals. We look forward to benefiting from Lantheus' experience and resources to further advance our pipeline and continue developing cutting-edge therapies and diagnostics that have the potential to transform patient care. I am very pleased to have our Evergreen team join another industry-leading company with a shared vision." Compelling Strategic and Financial Rationale Enhanced Radiopharmaceutical Manufacturing Infrastructure: The acquisition advances Lantheus' capabilities with the addition of Evergreen's radioligand therapy (RLT) manufacturing infrastructure, including a revenue-generating CDMO business. Evergreen's ability to work with a variety of diagnostic and therapeutic isotopes will enhance Lantheus' ability to address the complexities of radiopharmaceutical development and production. Internalizing this infrastructure will enable Lantheus to develop technical and operational expertise, supply its clinical trials, scale manufacturing for commercial launches, mitigate third party risk, and support long-term growth. Adds Near-Term Revenue with OCTEVY, which Complements PNT2003 Commercialization: Acquiring OCTEVY, a registrational-stage diagnostic imaging agent, provides Lantheus with additional growth potential while expanding its presence in NETs. Subject to FDA approval, OCTEVY is expected to be indicated for use with positron emission tomography (PET) for localization of somatostatin receptor-positive NETs in adult and pediatric patients. OCTEVY and Lantheus' PNT2003 could be used as a theranostic pair. Advanced Early Development Capabilities: Evergreen brings a fully integrated drug discovery and early-stage clinical development platform, promising early-stage oncology assets, and a highly skilled team that can generate novel targets and advance promising radiotherapeutic programs. Additional Transaction DetailsUnder the terms of the agreement, Lantheus will pay an upfront amount of $250 million, payable in cash at closing, and up to $752.5 million in development and sales milestones related to OCTEVY and Evergreen's clinical and pre-clinical pipeline. The transaction has been approved by the Boards of Directors of both companies and is expected to close in the second half of 2025, subject to customary closing conditions, including regulatory clearances. Company Reaffirms Full Year 2024 Financial GuidanceGuidance Issued November 6, 2024 FY 2024 Revenue $1.51 billion - $1.52 billion FY 2024 Adjusted Fully Diluted EPS $6.65 - $6.70 AdvisorsSolomon Partners Securities, LLC acted as financial advisor to Lantheus in this transaction, while Cooley LLP and Ropes & Gray LLP acted as legal advisors, and Ernst & Young LLP acted as financial and tax advisor. Centerview Partners LLC acted as financial advisor to Evergreen, while Skadden, Arps, Slate, Meagher & Flom LLP and Lowenstein Sandler LLP acted as legal advisors, and Grant Thornton Advisors LLC acted as tax advisor. Conference Call and Webcast DetailsLantheus will hold a conference call on Tuesday, January 28, 2025, at 8:30 AM ET. To access the live conference via webcast, please register here. A replay will be available after the conclusion of the call on Lantheus' investor website at: The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release. About Lantheus Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit About Evergreen Theragnostics, Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary products. Evergreen is headquartered in Springfield, NJ in a state-of-the-art GMP radiopharmaceutical facility. The company was founded in 2019 by a team that brings a strong track record in theranostic radiopharmaceutical manufacturing, research, and clinical development. For more information, please visit Safe Harbor for Forward-Looking and Cautionary StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as "continue," "may," "poised," "potential," "will," and other similar terms and include, among other things, statements about the potential benefits and results of the acquisition; the anticipated timing of the closing of the acquisition; the potential regulatory approval of OCTEVY™; the potential for OCTEVY™ and PNT2003 to be used as a theranostic pair; and Evergreen's ability to generate novel radiotherapeutic programs. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: Lantheus' and Evergreen's ability to complete the acquisition on the proposed terms or on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary regulatory approvals and satisfaction of other closing conditions to consummate the acquisition; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the proposed transaction; risks related to diverting the attention of Evergreen's and Lantheus' management from ongoing business operations; failure to realize the expected benefits of the acquisition; significant transaction costs and/or unknown or inestimable liabilities; the risk that Evergreen's business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for the combined company, including the uncertainty of expected future regulatory filings, financial performance and results of the combined company following completion of the acquisition; pharmaceutical product development and the uncertainty of clinical success; the regulatory approval process, including the risks that Evergreen may be unable to obtain regulatory approval for OCTEVY™ on the timeframe anticipated, or at all, or that Evergreen may be unable to obtain regulatory approvals of any of its other product candidates in a timely manner or at all; disruption from the proposed acquisition, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; effects relating to the announcement of the acquisition or any further announcements or the consummation of the acquisition on the market price of Lantheus' common stock; the possibility that, if Lantheus does not achieve the perceived benefits of the acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Lantheus' common stock could decline; potential litigation associated with the possible acquisition; and the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q). Contacts:Mark KinarneyVice President, Investor Relations978-671-8842ir@ Melissa DownsSenior Director, External Communications646-975-2533media@ View original content to download multimedia: SOURCE Evergreen Theragnostics, Inc. Sign in to access your portfolio
